With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

Fifteen-year-old Dominic Henriquez from Prosper, Texas, is bringing hope to boys like him who live with Hunter syndrome, a rare genetic disorder that primarily affects males. Dominic’s journey ...

On March 31, Neptune transitions from Pisces to Aries for the first time in our lives. However, it will return to Pisces on October 22 and stay there until 2026. During Neptune’s time in Pisces ...

The year 2025 can be the best year through spiritual changes, emphasizing gratitude, full moon rituals, daily meditation, time in nature, and journaling. These activities are designed to foster a ...

Bow Hunter's Syndrome (BHS) is a rare condition characterized by vertebrobasilar insufficiency, which occurs when the vertebral artery is compressed during head rotation. This compression can lead ...

The Moon, with its ever-changing phases, is a powerful ally in manifestation practices. Each phase carries unique energy, influencing everything from intentions to their fruition. Here’s how the ...

Storyline: When his abusive father’s actions cause him to escape home, Kraven finds haven in a sanctuary and turns into a hunter only to know that he’s being hunted As a fan of Hollywood films ...